Multiple sclerosis “win” makes the Principia shorts squirm

A positive clinical trial in multiple sclerosis with a mechanism that has so far failed to deliver would normally be hailed as a major medical advance. In the case of Principia’s BTK inhibitor SAR442168, however, the win is by no means clear-cut.